Clinical Trial Update: Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of hA20 (humanized anti-CD20) in CD20+ non-Hodgkin's lymphoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• hA20 (Humanized anti-CD20)

Snippet

Sponsor: Gilead Sciences | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED